AIM ImmunoTech (NYSE:AIM – Get Free Report) announced its earnings results on Wednesday. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.05), MarketWatch Earnings reports. The business had revenue of $0.05 million for the quarter. AIM ImmunoTech had a negative net margin of 10,764.25% and a negative return on equity of 67.33%.
AIM ImmunoTech Price Performance
Shares of AIM stock traded down $0.02 during trading hours on Friday, hitting $0.45. 200,447 shares of the company’s stock traded hands, compared to its average volume of 153,816. The stock’s fifty day simple moving average is $0.49 and its two-hundred day simple moving average is $0.54. AIM ImmunoTech has a 12-month low of $0.29 and a 12-month high of $0.84.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the stock. DRW Securities LLC purchased a new position in shares of AIM ImmunoTech in the 2nd quarter worth about $25,000. Renaissance Technologies LLC grew its holdings in shares of AIM ImmunoTech by 23.2% during the first quarter. Renaissance Technologies LLC now owns 168,708 shares of the company’s stock valued at $73,000 after buying an additional 31,800 shares during the last quarter. Virtu Financial LLC increased its holdings in shares of AIM ImmunoTech by 34.9% in the 1st quarter. Virtu Financial LLC now owns 50,805 shares of the company’s stock worth $54,000 after purchasing an additional 13,148 shares in the last quarter. State Street Corp boosted its stake in shares of AIM ImmunoTech by 7.9% in the 1st quarter. State Street Corp now owns 173,103 shares of the company’s stock worth $183,000 after buying an additional 12,690 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. bought a new position in shares of AIM ImmunoTech in the 1st quarter worth approximately $49,000. Hedge funds and other institutional investors own 12.75% of the company’s stock.
About AIM ImmunoTech
AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).
- Five stocks we like better than AIM ImmunoTech
- Stock Sentiment Analysis: How it Works
- 3 large caps with red hot RSIs with upside
- How to Invest in Solar Energy
- Johnson Controls International: Nothing but upside for investors
- How to Invest in Blue Chip Stocks
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for AIM ImmunoTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIM ImmunoTech and related companies with MarketBeat.com's FREE daily email newsletter.